Sinopharm Group Co. Ltd Cash Flow Quality Index
Sinopharm Group Co. Ltd cash flow quality index. Sinopharm Group Co. Ltd (X2S) has a Cash Flow Quality Index of -1.05x as of June 2023. Operating cash flow of €-2.63 Billion is below net income of €2.51 Billion, suggesting accrual-heavy earnings not yet converted to cash. See Sinopharm Group Co. Ltd (X2S) flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Sinopharm Group Co. Ltd (2013–2025)
Cash flow quality index of Sinopharm Group Co. Ltd from 2013 to 2025. Historical Cash Flow Quality Index for Sinopharm Group Co. Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Sinopharm Group Co. Ltd (X2S) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Sinopharm Group Co. Ltd Cash Flow Quality Index by Year (2013–2025)
Sinopharm Group Co. Ltd cash flow quality index by year from 2013 to 2025. Year-by-year earnings quality comparison for Sinopharm Group Co. Ltd. For the full cash flow conversion analysis, see Sinopharm Group Co. Ltd (X2S) cash conversion ratio.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.98x | €14.14 Billion | €7.16 Billion | ▲ +20.6% |
| 2024 | 1.64x | €11.55 Billion | €7.05 Billion | ▼ -13.7% |
| 2023 | 1.90x | €17.17 Billion | €9.05 Billion | ▼ -22.9% |
| 2022 | 2.46x | €20.96 Billion | €8.53 Billion | ▲ +105.0% |
| 2021 | 1.20x | €9.31 Billion | €7.76 Billion | ▼ -22.7% |
| 2020 | 1.55x | €11.15 Billion | €7.19 Billion | ▼ -48.3% |
| 2019 | 3.00x | €18.78 Billion | €6.25 Billion | ▲ +379.7% |
| 2018 | 0.63x | €3.65 Billion | €5.84 Billion | ▲ +8.8% |
| 2017 | 0.58x | €3.21 Billion | €5.58 Billion | ▼ -71.1% |
| 2016 | 1.99x | €9.26 Billion | €4.65 Billion | ▼ -44.0% |
| 2015 | 3.56x | €13.41 Billion | €3.77 Billion | ▲ +83.8% |
| 2014 | 1.93x | €5.56 Billion | €2.87 Billion | ▼ -11.9% |
| 2013 | 2.20x | €4.94 Billion | €2.25 Billion | — |